Skip to content

Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry

Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03479580
Acronym
3CRegistry
Enrollment
1600
Registered
2018-03-27
Start date
2018-02-08
Completion date
2028-02-29
Last updated
2022-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dilated Cardiomyopathies, Hypertrophic, Ischemic, Restrictive Cardiomyopathy

Keywords

Cardiomyopathy, Multimodal imaging, Coronary artery disease, Coronary microvascular disease, Prognosis, Atherosclerosis, Myocardial ischemia

Brief summary

Long-term prognostic value of macrovascular and microvascular coronary artery stenoses in each type of cardiomyopathy.

Detailed description

Coronary artery imaging techniques have taken a central role in the assessment of cardiovascular (CV) diagnosis over the past two decades. Many patients with a cardiomyopathy are also found to have a bystander coronary artery disease, not responsible for their cardiomyopathy. However, the prognostic value of those bystander coronary artery diseases is not known. Also, new imaging techniques have been developed to assess coronary microvascular disease, but the prognostic value of these findings is not known. In this study, the investigators evaluate the incidence and the prognosis of bystander coronary artery disease and microvascular disease in patients with ischemic, hypertrophic, dilated and restrictive cardiomyopathies in 5 French centers. Coronary angiography, cardiac magnetic resonance (CMR), tomographic coronary artery angiography, single-photon emission computed tomography (SPECT), rest and stress trans-thoracic echocardiography (TTE) results will be recorded. Macrovascular coronary artery disease is defined by : * a stenosis \> 50 % in coronary angiography confirmed with myocardial ischemia (SPECT, stress echocardiography), * a stenosis \> 70 % (50% if it is the left main coronary artery) * or a stenosis 30-70 % with a fractional flow reserve (FFR) \< 0.8 Microvascular disease is defined by an index of microvascular resistance (IMR) \>23 or myocardial perfusion heterogeneity imaging (MPHI) \> 4 using SPECT or CMR. Major adverse cardiovascular events (MACE) will be assessed 1 year, 2 years and 5 years after enrollment.

Interventions

OTHERPatients with a cardiomyopathy

Prognostic value of coronary artery disease and microvascular disease in the different types of cardiomyopathies.

Sponsors

Clinique Belledonne
CollaboratorUNKNOWN
Groupe Hospitalier Mutualiste de Grenoble
CollaboratorOTHER
Centre Hospitalier Annecy Genevois
CollaboratorOTHER
Centre Hospitalier Metropole Savoie
CollaboratorOTHER
University Hospital, Grenoble
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Ischemic * Dilated * Hypertrophic * Restrictive cardiomyopathy.

Exclusion criteria

* Pregnant women * Breastfeeding women * Patients under legal protection

Design outcomes

Primary

MeasureTime frameDescription
Major Adverse Cardiovascular Events5 yearsComposite outcome = rate of cardiovascular death, non-fatal myocardial infarction, need for myocardial revascularization by coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) \> 3 months after enrollment. During follow up

Countries

France

Contacts

Primary ContactClémence CHARLON
ccharlon@chu-grenoble.fr0033476766652

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026